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Abstract
Risk stratification of patients with pulmonary embolism (PE) may identify patients at high risk of early death who may
benefit from more intensive surveillance or aggressive therapy. Nontargeted proteomics may identify biomarkers useful for
the risk stratification of patients with acute symptomatic pulmonary embolism (PE). We studied 6 patients presenting with
low-risk PE and 6 patients presenting with intermediate (n = 3) or high-risk (n = 3) PE. Two-dimensional difference gel
electrophoresis was used to compare their plasma protein abundances. Candidate protein markers were identified by
matrix assisted laser desorption ionization time-of-flight mass spectrometry. A panel of four biomarkers (haptoglobin,
hemopexin, a2-macroglobulin, and Ig a1-chain C region) showed differences in plasma abundance among patients with
acute symptomatic PE of different severity. Haptoglobin and hemopexin were decreased, whereas a2-macroglobulin and Ig
a1-chain C region were increased, in patients with high or intermediate-risk PE compared with low-risk PE patient. In a
separate clinical population consisting of 104 adults with acute PE, serum haptoglobin concentrations had an 85% chance
of correctly identifying patients with high-risk PE according to receiving operating characteristics curve analysis. Moreover,
serum haptoglobin concentrations #1 g/l showed an 80% sensitivity and a 96% specificity for the diagnosis of high-risk PE.
Nontargeted proteomics identified protein biomarkers for the severity of PE that are involved in iron metabolism pathways
and acute-phase response. Among them, reduced serum haptoglobin concentrations show a high accuracy for the
biochemical detection of high-risk PE.
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Introduction
Venous thromboembolism (VTE) includes deep vein thrombosis
(DVT) and pulmonary embolism (PE). PE is a major cause of
mortality, morbidity, and hospitalization in Europe. On the basis
of an epidemiological model, it was estimated that over 317 000
deaths were related to VTE in six countries of the European
Union in 2004 [1]. Of them, 34% presented with fatal sudden PE
and 59% were deaths resulting from a PE that remained
undiagnosed during life; of note, only 7% of the patients who
died early had been diagnosed with PE before death.
Mortality rates in patients with objectively confirmed acute
pulmonary embolism (PE) vary from 1.4% to 17.4% during the
first three months of treatment [2,3,4,5], illustrating the hetero-
geneous clinical and prognostic spectrum of this disorder. Acute
complications (e.g., acute pulmonary arterial hypertension and
right heart failure) or recurrence of PE cause most early deaths,
whereas medical problems underlying PE are responsible for most
late deaths [6].
The initial management of PE aims to prevent fatal and non-
fatal recurrent venous thromboembolism and pulmonary arterial
hypertension from PE, while minimizing treatment-related com-
plications such as bleeding. For patients with concomitant deep
vein thrombosis, treatment objectives also include the prevention
of the post-thrombotic syndrome. Risk stratification of patients
with PE may identify patients at high risk of early death who may
benefit from more intensive surveillance or aggressive therapy (i.e.,
thrombolysis or embolectomy) [7,8]. Alternatively, patients
deemed low risk for early complications (i.e., death, recurrent
venous thromboembolism, and major bleeding) might be consid-
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ered for partial or complete outpatient treatment of their PE
[9,10].
Nontargeted proteomics may identify novel proteins associated
with different disease states [11,12,13]. To our best knowledge, no
exploratory proteomic studies of biomarkers of severity in patients
with PE have been published to date. Identification of novel
protein markers of the severity of PE might provide not only new
mechanistic insights but, more importantly, may facilitate
prospective risk assessment and risk reduction interventions.
Material and Methods
We conducted a nontargeted exploratory screening for markers
of severity in patients with acute symptomatic PE using two-
dimensional differential gel electrophoresis (2D-DIGE) of plasma
samples followed by matrix-assisted laser desorption/ionization–
time-of-flight/time-of-flight mass spectrometry (MALDI-TOF/
TOF MS). This approach allows high-throughput analysis of
thousands of proteins identifying, within a single experiment,
changes in abundance according to the severity of PE. The clinical
usefulness of the biomarkers identified by the nontargeted
proteomic experiment was then validated in a separate larger
population of patients with PE presenting with different risks and
severities.
Subjects
The nontargeted proteomics discovery study involved a total of
12 patients with acute PE. Patients were recruited at the
Department of Emergency Medicine of Hospital Ramo´n y Cajal.
Eligibility for this study required that patients presented with an
acute symptomatic PE that was confirmed by objective testing. Six
patients presenting with intermediate (n = 3) or high-risk (n = 3) PE
were compared with 6 patients presenting with low-risk PE). The
groups were similar in terms of age, body mass index (BMI) and
comorbid diseases such as cancer, chronic obstructive pulmonary
disease, and congestive heart failure (Table 1). The biomarkers
identified by the nontargeted proteomic study were then validated
by targeted approaches in an independent population consisting of
104 PE recruited consecutively at the Department of Emergency
Medicine. The validation study included 5 patients with high-risk
PE, 47 patients with intermediate-risk PE, and 52 patients with
low-risk PE (Table 2). Blood samples were obtained approximately
at the time of diagnosis of PE, and never beyond the first 24 hours
after diagnosis. Fasting was not required for testing. The
Institutional Review Board of Hospital Ramo´n y Cajal approved
the study and all patients provided written informed consent.
Diagnosis and risk-assessment of PE
The clinical suspicion of PE was confirmed in all subjects by a
high probability ventilation-perfusion scan result according to the
criteria of the Prospective Investigation of Pulmonary Embolism
Diagnosis [14], a lower limb venous compression ultrasonography
positive for a proximal deep vein thrombosis in patients with
inconclusive or non-diagnostic ventilation-perfusion scans [15], or
by contrast-enhanced PE-protocol chest multidetector computed
tomography [16].
The risk assessment defined a high-risk PE by the presence of
clinically overt right ventricle failure resulting in hemodynamic
compromise (shock or persistent arterial hypotension; i.e., a
systolic blood pressure ,90 mmHg or a pressure drop of .
40 mmHg for 15 min); an intermediate-risk PE by the presence of
echocardiographic signs of right ventricle dysfunction [17]; and a
low-risk PE by exclusion of right ventricle dysfunction and
negative myocardial injury markers. These PE risk definitions
were applied in both the discovery and the clinical validation
studies.
Plasma proteomic analyses
Detailed information of proteomic techniques, together with the
randomization and combination of samples and MS analysis of
protein spots, is included in the Minimum Information About
Proteomics Experiment (MIAPE) document (Table S1).
Blood samples were obtained in glass vials containing disodium
EDTA (Vacutainer K3E 7.2 mg, BD, Franklin Lakes, NJ, USA).
Plasma was recovered by centrifugation at 13006g and 4uC for
10 min, and stored at 280uC until assayed. We removed albumin
and IgG from plasma applying the albumin and IgG removal kit
(GE healthcare, Buckinghamshire, UK) and we dissolved the
samples in 1 ml of ice-cold distilled water, and concentrated them
by ultrafiltration using a pore-size of 10,000 Da (Amicon Ultra;
Millipore, Bedford, MA, USA). Subsequently, we resuspended
samples in 200 ml of lysis buffer and applied a second ultrafiltration
to obtain a final volume of approximately 70 ml. Finally, we
measured protein concentration using the RD-DC Protein Assay
(Bio-Rad, Hercules, CA, USA). To evaluate the reproducibility of
the extraction, all the samples were separated with 12% SDS-
PAGE, 4 mg protein per lane, and silver stained (data not shown)
[18].
The techniques used for protein labeling, two-dimensional
electrophoresis, 2D-DIGE, image analysis and protein identifica-
tion have been published earlier [19,20,21]. MALDI-TOF/TOF
mass spectrometry (MS) analyses were performed in a 4800
Proteomics Analyzer (Applied Biosystems, MDS Sciex, Toronto,
Canada) at the Genomics and Proteomics Center, Universidad
Complutense, Madrid.
Experimental design and data analysis
For 2D-DIGE experiments, DeCyder 7.0 (GE Healthcare Bio-
Sciences AB, Uppsala, Sweden) differential in gel analysis (DIA)
module was used for intra-gel co-detection of samples and internal
standard protein spots allowing the detection of an average of
1,707 protein spots (7.85% coefficient of variation [CV]) on each
image. Artifactual spots were filtered and removed.
We evaluated the differences in protein abundance in plasma
proteins between 6 patients with low-risk PE, and a group of 6
patients that considered, as a whole, 3 subjects with intermediate-
risk PE together with 3 subjects with high-risk PE (2 groups, 12
samples, 6 gels). To avoid any possible bias introduced by labeling
efficiency, half of the samples from each group were labeled with
Cy3 dye and the other half with Cy5 dye. A pool of all the samples
labeled with Cy2 served as the internal standard used for
normalization of the results. The 18 images from the 6 gels were
submitted to DeCyder biological variation analysis module.
Biological variation analysis served for inter-gel matching of
internal standard and samples across all gels, and for comparative
cross-gel statistical analyses of all spots, based on spot volumes,
permitting the detection of spots with different abundance between
groups. The difference between two samples is reported as a
volume ratio. In this step, an average of 1,141 spots was matched
on the gels (11.5% CV). The spots volumes of all matched proteins
spots were normalized and quantified. Only spots present in 14 out
of the 16 gel images were considered. Finally, protein spot matches
and data quality were verified manually to exclude artifacts and to
avoid false positives. The normalized volume data for each spot
obtained from patients and from controls were exported using the
XML toolbox and submitted to statistical analysis.
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Table 1. Clinical characteristics of the patients included in the two-dimensional difference gel electrophoresis nontargeted
proteomic marker discovery study.
Low-risk PE Intermediate or high-risk PE P
n = 6 n = 6
Clinical characteristics
Age, years 80.265.7 80.066.3 0.699
Male sex 2 (33%) 2 (33%) 0.999
BMI, kg/m2 25.463.0 24.062.7 0.405
Risk factors for venous thromboembolism
Cancer* 0 (0%) 0 (0%) -
Recent surgery{ 1 (17%) 0 (0%) 0.296
Immobilization` 1 (17%) 2 (33%) 0.505
Comorbidities
Chronic obstructive pulmonary disease 0 (0%) 0 (0%) -
Congestive heart failure 0 (0%) 0 (0%) -
Echocardiography and cardiac biomarkers
RV dysfunction (echocardiogram) 0 (0%) 6 (100%) -
BNP, pg/ml 2926395 4906274 0.132
cTnI, ng/ml 0 0.1260.12 0.065
Data are means 6 SD or counts (percentage).
Abbreviations: BMI, body mass index; BNP, brain natriuretic peptide; cTnI, cardiac troponin I; PE, pulmonary embolism; RV, right ventricle.
*Active or under treatment in the last year.
{In the previous month.
`Immobilized patients are defined in this analysis as non-surgical patients who had been immobilized (i.e., total bed rest with bathroom privileges) for $4 days in the
month prior to PE diagnosis.
doi:10.1371/journal.pone.0100902.t001
Table 2. Clinical variables of the patients included in the clinical validation study.
Low-risk PE Intermediate or high-risk PE P
n = 52 n = 52
Clinical characteristics
Age, years 70.6616.8 67.1616.8 0.128
Male sex 21 (40%) 23 (44%) 0.754
BMI, kg/m2 27.866.7 25.964.1 0.252
Risk factors for venous thromboembolism
Cancer* 7 (13%) 13 (25%) 0.148
Recent surgery{ 4 (7.7%) 4 (7.7%) 0.977
Immobilization` 11 (21%) 5 (9.6%) 0.094
Comorbidities
Chronic obstructive pulmonary disease 5 (9.6%) 4 (7.7%) 0.704
Congestive heart failure 1 (1.9%) 2 (3.8%) 0.569
Echocardiography and cardiac biomarkers
RV dysfunction (echocardiogram) 0 (0%) 52 (100%) ,0.001
BNP, pg/ml 45623 4566800 ,0.001
cTnI, ng/ml 0.00160.01 0.1560.26 ,0.001
Data are means 6 SD or counts (percentage).
Abbreviations: BMI, body mass index; BNP, brain natriuretic peptide; cTnI, cardiac troponin I; PE, pulmonary embolism; RV, right ventricle.
*Active or under treatment in the last year.
{In the previous month.
`Immobilized patients are defined in this analysis as non-surgical patients who had been immobilized (i.e., total bed rest with bathroom privileges) for $4 days in the
month prior to PE diagnosis.
doi:10.1371/journal.pone.0100902.t002
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Haptoglobin assay and genotypes
The circulating concentrations of haptoglobin were assayed by a
commercial immunonephelometry method (Dade Behring, Mar-
burg, Germany) calibrated against the international CRM 470
reference material [22] with intra-assay and inter-assay CVs of
2.6% and 6.2%, respectively. Immunonephelometry uses specific
antibodies to determine the concentrations of haptoglobin in a
suspension. This technique is based on the light-scattering
properties of the resulting immune complexes, because the scatter
of light and its maximal value increase with the concentration of
haptoglobin in the sample.
Genomic DNA was obtained from blood samples using the
FujiFilm QuickGene DNA whole blood kit S (FujiFilm Corpora-
tion, Tokyo, Japan) and the haptoglobin a–chain polymorphism
genotypes were assessed using the polymerase chain reaction-
based technique. Two different PCR products were amplified to
determine Hp1 and Hp2 alleles using primer pairs A–B and C–D
(Sigma-Aldrich), previously described by Koch et al. [23].
Reactions were performed in a 2720 Thermal Cycler (Applied
Biosystems) in a final volume of 20 ml containing 2 U of FastStart
Taq DNA polymerase (Roche Diagnostics), 50–100 ng of DNA,
and 200 mM each dNTP. Reactions with primers A and B
required 1.5 mM MgCl2 and 5% DMSO and the following
amplification protocol: denaturation at 95uC for 5 min, 35 cycles
of denaturation at 95uC for 1 min and annealing/extension at
69uC for 3 min, and a final extension at 72uC for 7 min. Reactions
with primers C and D required 2 mM MgCl2 and the following
amplification protocol: denaturation at 94uC for 5 min, 35 cycles
of denaturation at 94uC for 1 min, annealing at 69uC for 1 min
and extension at 72uC for 1 min, and a final extension at 72uC for
7 min. PCR products were resolved in 0.8% and 1.6% agarose
gels, respectively.
Hemopexin assay
We measured plasma hemopexin concentrations using a
commercial ELISA kit (ab108859 Hemopexin Human ELISA
kit) following manufacturer’s instructions (Abcam plc, Cambridge,
UK). The samples from all subjects were assayed in duplicate. The
lower limit of detection was 0.07 mg/ml and the mean intra- and
inter-assay CVs were 5% and 7.7%, respectively.
Statistical analysis
We expressed continuous variables as means 6 SD and
dichotomous variables as counts (percentages) unless otherwise
stated. We selected a 1.5-fold difference in protein abundance
between groups as the cut-off that excluded experimental
variability in comparative proteomic analysis of depleted plasma
samples, as determined in our laboratory in previous experiments
that used exactly the same methods employed here [19]. After
confirming the normal distribution of the variables by the
Kolmogorov-Smirnov test, the differences in protein abundance
between groups were analyzed by ANOVA. The comparisons of
clinical and biochemical variables between the 2 groups of patients
with PE included in the discovery study used Mann-Whitney U
tests, x2 tests or Fisher’s exact tests as appropriate. Differences in
serum haptoglobin and hemopexin concentrations among groups
in the larger validation study were analyzed by one-way ANOVA
followed by the least significant difference posthoc test. The
accuracy of these protein markers for the diagnosis of high-risk
PE was assessed by receiver operating characteristic (ROC) curve
analysis. We used SPSS Statistics 17 (SPSS, Chicago, IL) for all
statistical analyses. p,0.05 was considered statistically significant.
Results
Differences in protein abundance between patients with
low-risk PE and patients with intermediate or high-risk PE
The clinical and biochemical characteristics of the patients
included in the discovery study are summarized in Table 1. After
2D-DIGE, DeCyder software indicated that the protein abun-
dance of 10 spots reached statistically significant differences, with
fold differences above 1.5, among patients with low-risk PE and
individuals presenting with intermediate or high-risk PE. Figure 1
shows a representative 2D-DIGE map of plasma protein extracts
including the pick locations of the spots identified. After in-gel
digestion and MALDI-TOF/TOF analysis, a Mascot database
search using the peptide mass fingerprinting spectra allowed the
identification of the protein present in 1 spot, whereas the proteins
of another 9 spots were identified by tandem mass spectrometry.
Detailed information of the identification of these 10 spots is
summarized in Table 3, including their accession numbers,
theoretical molecular weight (MW) and isoelectric point (pI)
values, DeCyder software and identification method parameters.
The 10 spots showing differences in abundance corresponded to
only 4 proteins, because 2 of the proteins identified were present in
more than one spot suggesting post-translational modification or
proteolysis. 2D-DIGE analysis showed that four protein species
corresponding with Ig a1-chain C region and one protein species
of a2-macroglobulin were increased in the plasma samples from
patients with intermediate or high-risk PE. On the other hand,
three protein species corresponding to haptoglobin and one
protein species of hemopexin were decreased compared with
patients with acute low-risk PE.
Validation of candidate markers in the clinical validation
population
We then proceeded to validate in a separate clinical population
the two candidate biomarkers (hemopexin and haptoglobin) more
likely to play a role in PE according to our current knowledge
about the pathophysiology of this disorder. This population
consisted of 52 adults with intermediate (n = 47) or high-risk (n = 5)
PE, who were compared with 52 patients with low-risk PE, whose
clinical and biochemical characteristics are summarized in Table 2.
Confirming proteomic results, patients with intermediate or
high-risk PE exhibited a significant decrease in serum concentra-
tions of haptoglobin compared with patients with low-risk PE
(2.360.8 vs 2.661.0 g/l respectively, P = 0.045), and such a
decrease was especially marked in patients with high-risk PE
(Figure 2). On the contrary, hemopexin concentrations as
determined by ELISA did not show statistically significant
differences between the groups of patients with PE of different
severity, either when comparing the 52 patients with intermediate
or high-risk PE with the 52 patients with low-risk PE (3666163 vs
3796170 mg/ml respectively, P = 0.684), or when comparing low-
risk, intermediate-risk and high-risk PE patients separately
(Figure 2).
Because Hp2 alleles of the haptoglobin a–chain polymorphism
reduce serum concentrations and anti-oxidant properties and
increase the pro-inflammatory actions of this acute-phase protein
in a gene-dosage fashion [24], we analyzed the distribution of this
polymorphism in the validation study to find out if the differences
observed in serum haptoglobin concentrations in patients with
high-risk PE were dependent on a genetic predisposition.
In our series, haptoglobin a–chain genotypes were distributed
according to Hardy-Weinberg equilibrium in all the groups of
patients (data not shown). As expected from previous studies [24],
subjects homozygous for Hp2 alleles as a whole showed decreased
Haptoglobin and Severity of Pulmonary Embolism
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circulating levels of haptoglobin compared with subjects carrying
Hp1 alleles (Hp1/1: 2.660.6 g/l; Hp1/2: 2.760.9 g/l; Hp2/2:
2.160.9 g/l, P = 0.003). The distribution of haptoglobin geno-
types was not different between the low-risk PE patients and those
presenting with intermediate or high-risk PE (low-risk PE: Hp1/1,
n = 7, Hp1/2, n = 22, Hp2/2, n = 23; intermediate or high-risk
PE: Hp1/1, n = 8, Hp1/2, n = 25, Hp2/2, n = 19; x2 = 0.639,
P = 0.726, the intermediate and high-risk categories had to be
combined into a category to meet the x2 requirement that less than
20% of the expected frequencies are less than 5).
We used separate ROC curve analyses to assess the diagnostic
accuracy of circulating haptoglobin and hemopexin as biomarkers
of high-risk PE (Figure 3). Circulating haptoglobin showed a 0.853
area under the ROC curve (95% confidence interval 0.6482
1.057, P = 0.008) for the detection of high-risk PE in our series,
whereas circulating hemopexin was not useful for this purpose
showing a 0.567 area under the ROC curve (95% confidence
interval 0.32920.806, P = 0.613). A circulating haptoglobin value
equal or below 1 g/l showed a 80% sensitivity and a 96%
specificity for the diagnosis of high-risk PE.
Finally, 6 of the 104 patients included in the validation sample
(5.8%; 95% CI of the proportion: 2.4%212.6%) died from PE
within thirty days of presentation. For 2 patients in the validation
cohort who died, reclassification was more accurate when
haptoglobin was combined with the presence of high-risk PE,
resulting in a 33.3% increase in nonsurvivors correctly identified as
being at high risk. The net improvement in reclassification was
estimated at 0.32 when considering serum haptoglobin values.
Discussion and Conclusions
Our present nontargeted proteomic discovery study has
identified a panel of protein markers whose serum concentrations
are significantly altered according to the severity of PE. The
functions of these proteins points to novel mechanistic pathways
indicating the involvement of iron metabolism and complement
pathways, and of the coagulation cascade in the mechanisms that
determine the severity of PE. We have validated these results in a
second clinical population of patients with PE identifying reduced
haptoglobin concentrations as a serum protein biomarker that
may be used in combination with clinical and echocardiographic
data with the aim to identify patients at high-risk of PE-related
complications.
The biomarker panel comprises positive acute-phase proteins
such as a2-macroglobulin and Ig a1-chain C region (that were
more abundant) and haptoglobin and hemopexin (that were less
abundant) in patients with high-risk compared with less severe PE
patients. The acute-phase response is an innate body defense
Figure 1. Representative two dimensional-differential in-gel electrophoresis (2D-DIGE) map of depleted plasma proteins including
the pick locations of the proteins identified in the study (Panel A). Magnification of the area including the haptoglobin spots (indicated by
the line markers) in the 12 gels (Panel B).
doi:10.1371/journal.pone.0100902.g001
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observed during infection, physical trauma, malignancy, and tissue
damage that aims to minimize on-going tissue damage by isolating
and destroying infective agents while activating repair processes.
The innate immune response involves the recruitment and
activation of macrophages and leukocytes that release inflamma-
tory cytokines on recognition of a pathogen-associated molecular
pattern. These cytokines travel through the bloodstream and
stimulate hepatocytes in the liver to synthesize and secrete acute-
phase proteins.
The acute-phase proteins identified here in association with the
severity of PE are predominantly liver-synthesized proteins that
have an important antiinflammatory activity through inhibition of
oxidative stress and iron sequestration resulting in antimicrobial
activity. As such, they may function to modulate the systemic
inflammatory response to inflammation [25] and be involved in
tissue repair through fibrosis and angiogenesis [26,27].
In addition, both haptoglobin and hemopexin are involved in
iron metabolism. The inhibition of heme release from hemoglobin
by haptoglobin and sequestration of heme by hemopexin suppress
hemoglobin-mediated oxidative stress, attenuate endothelial cyto-
toxicity, and protect cells from heme toxicity [24,28]. In addition,
hemoglobin and its derivative heme are often released into tissue
compartments where there is inflammation, in the presence of
degrading blood, and hemoglobin synergizes with multiple toll-like
Figure 2. Serum haptoglobin and hemopexin concentrations in
the diagnostic validation series consisting of 52 patients with
low-risk pulmonary embolism (PE), 47 patients with interme-
diate PE and 5 patients with high-risk PE. Bars are means and 95%
confidence intervals. Asterisk represents patients who died of PE. Data
were submitted to one-way ANOVA followed by the least-significant
difference posthoc test. Serum haptoglobin concentrations were
determined by immunonephelometry and hemopexin levels were
measured by ELISA.
doi:10.1371/journal.pone.0100902.g002
Figure 3. Receiver operating characteristic curve analysis of
serum haptoglobin and hemopexin concentrations for the
diagnosis of high-risk pulmonary embolism. The areas under the
ROC curves were 0.853 (95% confidence interval 0.64821.057, P = 0.008)
for haptoglobin, and 0.567 (95% confidence interval 0.32920.806,
P = 0.613) for hemopexin.
doi:10.1371/journal.pone.0100902.g003
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receptor agonists to induce release of high levels of tumor necrosis
factor and interleukin-6 from macrophages, an effect that is
attenuated by hemopexin [29]. Hemopexin also down-regulates
lipopolysaccharide-induced proinflammatory cytokine release
from macrophages [30].
Of the 4 proteins identified by the nontargeted proteomic study
we were able to confirm, in a much larger validation study, that
serum haptoglobin concentrations are actually decreased in the
most severe forms of PE, in conceptual agreement with previous
animal and human studies on the issue [31,32,33]. Severe PE
causes turbulent flow across the tricuspid and pulmonic valves and
in the pulmonary tree and may rupture red cells in, or immediately
proximal to, or within, the pulmonary vascular tree [31].
Hemolysis then results in a transient increase in unbound
hemoglobin and free heme immediately proximal to the lung.
This timing and location of this shear effect requires release of an
only a small amount of free hemoglobin to have a profound effect
on pulmonary vascular tone. Upon its rupture, the erythrocyte
releases tetrameric (a2b2) hemoglobin, which can avidly bind
nitric oxide, but must first dissociate into ab dimers before
haptoglobin can bind and inactivate this nitric oxide scavenging
effect [34].
The decrease in serum haptoglobin found in patients high-risk
PE could result from at least two hypothetical mechanisms. On the
one hand, because haptoglobin’s protective role against intravas-
cular hemolysis, possibility existed that subjects carrying Hp2
alleles of the haptoglobin a–chain polymorphism, by having lower
serum haptoglobin levels, would be at risk for more severe
consequences of PE (i.e. their defense against intravascular
hemolysis would have been less effective). Our present results,
showing no association of Hp alleles with the severity of PE, weight
heavily against this possibility. On the other hand, consumption of
haptoglobin in order to prevent the liberation of heme from the
intravascular hemoglobin liberated in severe PE during intravas-
cular hemolysis may explain the decrease in haptoglobin
concentrations observed in our high-risk PE patients [24]. Other
disorders that may decrease haptoglobin concentration such as
malnutrition or severe hepatic disease [24] were not present in the
patients studied here.
A possible limitation of our study is that the diagnostic utility of
plasma haptoglobin as a biomarker of hemolysis in patients with
PE might be confounded by a positive acute phase reactant effect,
resulting in spuriously elevated haptoglobin concentrations,
probably as a result of the underlying inflammatory and
thrombophilic factors that caused the patient’s venous thrombosis
[24]. However, the significant results from the validation cohort,
showing reduced serum haptoglobin levels in patients with severe
PE despite the possible interference of a positive acute phase
response, provided evidence of the robustness of the findings and
further strengthened the soundness of the abovementioned
hypothesis.
Even though another potential limitation of the study is the
small number of patients in the high risk stratification group, it is
noteworthy that ROC curve analysis indicated that reduced serum
haptoglobin concentrations show a very good diagnostic accuracy
for high-risk PE – a single haptoglobin determination has an 85%
chance of correctly identifying patients with high-risk PE – and
that using a #1 g/l cut-off value, serum haptoglobin concentra-
tion has 80% sensitivity and 96% specificity for the detection of the
most severe forms of PE in a clinical setting. These promising
results require future confirmation in larger series of unselected
patients with PE.
In conclusion, this report shows that circulating haptoglobin is
decreased in patients with severe PE. The decrease in serum
haptoglobin may arise from a protective response against
intravascular hemolysis, further supporting current hypotheses
that suggest intravascular hemolysis as a contributor to pulmonary
hypertension in patients with severe acute PE. Finally, reduced
serum haptoglobin concentration should be considered a prom-
ising protein marker of the most severe forms of PE.
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